Imagine a smart health filter that catches dementia long before the usual symptoms appear. It combines simple home tests, like a finger-prick of blood, with brain scans and AI to spot warning signs. This allows doctors to step in early and give people a better chance at a healthier life.
Healthcare systems lack scalable, low-cost tools to identify dementia risk early. This leads to delayed treatment and increased financial and personal burdens on patients and providers.
An AI-driven digital platform for dementia risk assessment and the PROTECT tool for home self-monitoring.
If you are a lab test manufacturer dealing with the need for non-invasive screening — this project developed a platform that integrates blood, saliva, and stool biomarkers. This allows for high-volume, low-threshold testing at the point of care.
If you are a health-tech developer dealing with patient monitoring gaps — this project developed the PROTECT tool for home self-monitoring. This creates a continuous data stream for early risk assessment and prognosis.
If you are a clinic network dealing with inefficient dementia triage — this project developed an AI-driven screening platform. This helps stratify patients into personalized interventions, reducing the burden on specialized memory clinics.
Based on available project data, specific pricing or cost figures are not provided, although the platform is intended to be open-source to save time and money.
Yes, the project specifically aims to establish scalable and cost-efficient diagnostic markers and procedures for general population screening.
The project objective states the development of an open-source biomarker screening platform, suggesting a non-proprietary licensing model for the core platform.
The platform is designed to be interoperable and customizable, allowing for data exchange between different healthcare systems and actors.
The project period runs from 2023-11-01 to 2027-10-31, indicating the full system will be refined over these four years.
The consortium is heavily industry-weighted with 22 industrial partners (59% ratio), including 9 SMEs. This strong commercial presence, spanning 15 countries, suggests a high focus on market viability and practical implementation rather than purely academic research.
Contact HELSE STAVANGER HF in Norway
Contact us to explore licensing opportunities for the open-source screening platform.
